Enanta Pharmaceuticals Inc. has divulged macrocyclic chalcone-amide compounds acting as non-structural protein 3 (nsp3; PL-pro) (SARS-CoV-2; COVID-19 virus) inhibitors.
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Ascentage, Belite, Revive.
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Almirall, Astrazeneca, Bioarctic, Eisai, Entos, GC, GSK, Moderna, Novel, Roche, Santhera, Shattuck.
Clinical updates, including trial initiations, enrollment status and data readouts and publications: 4D, 4Moving, Actinium, Arcturus, Eli Lilly, Genentech, Longboard, Moderna, Oculis, Pacylex, Prokidney, Sellas, Skye, Surrozen, Tharimmune, Vertex.
Moderna Inc. is gearing up to meet with regulators on the next steps for mRNA-1083, the first combination vaccine for influenza and COVID-19 to succeed in phase III testing, not only demonstrating noninferiority to individually licensed competitor vaccines but also eliciting statistically significant higher immune responses.
Emory University has identified 3C-like proteinase (3CLpro; Mpro; nsp5) (SARS-CoV-2; COVID-19 virus) inhibitors reported to be useful for the treatment of SARS-CoV-2 infection (COVID-19).
Exevir Bio BV has demonstrated that its antibodies are potent in neutralizing the SARS-CoV-2 variant JN.1, the parental strain of the currently most dominantly circulating variants worldwide.
Although consensus was not reached on the World Health Organization’s pandemic agreement, the World Health Assembly recognized the progress made by member states to develop a pandemic agreement and to strengthen International Health Regulations (IHR, 2005) during the 77th World Health Assembly meeting held May 27 to June 1 in Geneva.
RSS
